The zaltrap market research report is one of a series of new reports that provides zaltrap market statistics, including the zaltrap industry global market size, regional shares, competitors with the zaltrap market share, detailed zaltrap market segments, market trends, and opportunities, and any further data you may need to thrive in the zaltrap industry. This zaltrap market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The growth in the forecast period can be attributed to the rising incidence of colorectal cancer globally, increasing government initiatives supporting cancer research funding, growth of patient-centric initiatives, rising global focus on cancer research funding, and rising prevalence of co-morbid conditions. Major trends in the forecast period include advancements in drug delivery systems, advancements in imaging technologies, advancements in biomarker identification, integration of artificial intelligence in drug development processes, and advancements in nanotechnology.
The increasing prevalence of colorectal cancer is anticipated to drive the growth of the Zaltrap market. Colorectal cancer, which originates in the colon or rectum, often begins as benign polyps that can progress if not treated. The rising rates of colorectal cancer are linked to factors such as an aging population, unhealthy diets, obesity, and genetic factors. Zaltrap is a vascular endothelial growth factor (VEGF) inhibitor that blocks the formation of new blood vessels, depriving the tumor of its blood supply. This helps slow the progression of the disease and improves survival outcomes for patients. For example, in July 2024, Bowel Cancer UK reported that approximately 44,000 people are diagnosed with bowel cancer annually in the UK, with the majority (94%) of cases occurring in those aged 50 or older. Despite this, bowel cancer can affect people of all ages, with over 2,600 new cases diagnosed each year in those under 50. Therefore, the increasing prevalence of colorectal cancer is fueling the demand for Zaltrap.
The rise in cancer care spending is also expected to drive the growth of the Zaltrap market. Cancer care expenditure covers all costs associated with the prevention, diagnosis, treatment, and follow-up care of cancer, including both medical and non-medical expenses. The growth in cancer care spending is driven by factors such as the increasing number of cancer cases, advancements in treatment technologies, and the growing population of cancer survivors who require ongoing care. As spending on cancer care increases, there is a heightened focus on effective and targeted treatments, with research and clinical trials playing a key role in the development and adoption of Zaltrap. For instance, in September 2024, Cancer Research UK reported that £399 million was allocated to cancer research in the 2023/24 financial year, with significant portions directed toward general cancer research and basic research exploring cancer's biology. This growing expenditure on cancer care is contributing to the growth of the Zaltrap market.
The expanding aging population is also playing a significant role in the growth of the Zaltrap market. An aging population is characterized by an increasing number of individuals aged 60 or 65 and older, driven by factors such as longer life expectancies, declining fertility rates, and better support systems for older adults. Metastatic colorectal cancer is more common in the aging population, and Zaltrap offers an effective treatment option for these patients. By inhibiting VEGF and slowing tumor growth, Zaltrap helps improve outcomes and quality of life for older cancer patients. For instance, in January 2024, the Population Reference Bureau projected that the number of Americans aged 65 and older would grow from 58 million in 2022 to 82 million by 2050, an increase of 47%. This age group’s share of the population is expected to rise from 17% to 23% over the same period. As the population of older individuals grows, the demand for Zaltrap is expected to increase.
The key company operating in the zaltrap market is Sanofi S.A.
North America was the largest region in the zaltrap market in 2024. The regions covered in zaltrap report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the zaltrap market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Zaltrap is a prescription medication used in combination with other chemotherapy drugs to treat metastatic colorectal cancer (mCRC). It is a VEGF inhibitor that targets VEGF-A, VEGF-B, and placental growth factor (PlGF), blocking angiogenesis and the formation of new blood vessels that tumors need to grow and spread, thereby slowing disease progression.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main indications for zaltrap include metastatic colorectal cancer (mCRC) and metastatic breast cancer. mCRC is an advanced stage of colorectal cancer where the disease has spread to distant organs such as the liver or lungs. Zaltrap is available in injection formulations (100 mg/4 ml, 200 mg/8 ml) and is distributed through various channels, including hospitals, oncology clinics, and pharmacies. It is used by a range of patients, including adults and the elderly.
The zaltrap market consists of sales of single-dose vials, prefilled syringes, and lyophilized powder for reconstitution. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to the rising incidence of colorectal cancer globally, increasing government initiatives supporting cancer research funding, growth of patient-centric initiatives, rising global focus on cancer research funding, and rising prevalence of co-morbid conditions. Major trends in the forecast period include advancements in drug delivery systems, advancements in imaging technologies, advancements in biomarker identification, integration of artificial intelligence in drug development processes, and advancements in nanotechnology.
The increasing prevalence of colorectal cancer is anticipated to drive the growth of the Zaltrap market. Colorectal cancer, which originates in the colon or rectum, often begins as benign polyps that can progress if not treated. The rising rates of colorectal cancer are linked to factors such as an aging population, unhealthy diets, obesity, and genetic factors. Zaltrap is a vascular endothelial growth factor (VEGF) inhibitor that blocks the formation of new blood vessels, depriving the tumor of its blood supply. This helps slow the progression of the disease and improves survival outcomes for patients. For example, in July 2024, Bowel Cancer UK reported that approximately 44,000 people are diagnosed with bowel cancer annually in the UK, with the majority (94%) of cases occurring in those aged 50 or older. Despite this, bowel cancer can affect people of all ages, with over 2,600 new cases diagnosed each year in those under 50. Therefore, the increasing prevalence of colorectal cancer is fueling the demand for Zaltrap.
The rise in cancer care spending is also expected to drive the growth of the Zaltrap market. Cancer care expenditure covers all costs associated with the prevention, diagnosis, treatment, and follow-up care of cancer, including both medical and non-medical expenses. The growth in cancer care spending is driven by factors such as the increasing number of cancer cases, advancements in treatment technologies, and the growing population of cancer survivors who require ongoing care. As spending on cancer care increases, there is a heightened focus on effective and targeted treatments, with research and clinical trials playing a key role in the development and adoption of Zaltrap. For instance, in September 2024, Cancer Research UK reported that £399 million was allocated to cancer research in the 2023/24 financial year, with significant portions directed toward general cancer research and basic research exploring cancer's biology. This growing expenditure on cancer care is contributing to the growth of the Zaltrap market.
The expanding aging population is also playing a significant role in the growth of the Zaltrap market. An aging population is characterized by an increasing number of individuals aged 60 or 65 and older, driven by factors such as longer life expectancies, declining fertility rates, and better support systems for older adults. Metastatic colorectal cancer is more common in the aging population, and Zaltrap offers an effective treatment option for these patients. By inhibiting VEGF and slowing tumor growth, Zaltrap helps improve outcomes and quality of life for older cancer patients. For instance, in January 2024, the Population Reference Bureau projected that the number of Americans aged 65 and older would grow from 58 million in 2022 to 82 million by 2050, an increase of 47%. This age group’s share of the population is expected to rise from 17% to 23% over the same period. As the population of older individuals grows, the demand for Zaltrap is expected to increase.
The key company operating in the zaltrap market is Sanofi S.A.
North America was the largest region in the zaltrap market in 2024. The regions covered in zaltrap report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the zaltrap market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Zaltrap is a prescription medication used in combination with other chemotherapy drugs to treat metastatic colorectal cancer (mCRC). It is a VEGF inhibitor that targets VEGF-A, VEGF-B, and placental growth factor (PlGF), blocking angiogenesis and the formation of new blood vessels that tumors need to grow and spread, thereby slowing disease progression.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main indications for zaltrap include metastatic colorectal cancer (mCRC) and metastatic breast cancer. mCRC is an advanced stage of colorectal cancer where the disease has spread to distant organs such as the liver or lungs. Zaltrap is available in injection formulations (100 mg/4 ml, 200 mg/8 ml) and is distributed through various channels, including hospitals, oncology clinics, and pharmacies. It is used by a range of patients, including adults and the elderly.
The zaltrap market consists of sales of single-dose vials, prefilled syringes, and lyophilized powder for reconstitution. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Zaltrap Market Characteristics4. Zaltrap Market Trends And Strategies5. Zaltrap Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Zaltrap Pricing Analysis & Forecasts30. Global Zaltrap Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Zaltrap Market32. Recent Developments In The Zaltrap Market
3. Zaltrap Market Biologic Drug Characteristics
6. Global Zaltrap Growth Analysis And Strategic Analysis Framework
8. Zaltrap Market Segmentation
9. Global Zaltrap Epidemiology Of Clinical Indications
10. Zaltrap Market Regional And Country Analysis
11. Asia-Pacific Zaltrap Market
12. China Zaltrap Market
13. India Zaltrap Market
14. Japan Zaltrap Market
15. Australia Zaltrap Market
16. South Korea Zaltrap Market
17. Western Europe Zaltrap Market
18. UK Zaltrap Market
19. Germany Zaltrap Market
20. France Zaltrap Market
21. Eastern Europe Zaltrap Market
22. North America Zaltrap Market
23. USA Zaltrap Market
24. Canada Zaltrap Market
25. South America Zaltrap Market
26. Middle East Zaltrap Market
27. Africa Zaltrap Market
28. Zaltrap Market Competitive Landscape And Company Profiles
29. Global Zaltrap Market Pipeline Analysis
33. Zaltrap Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Zaltrap Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on zaltrap market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for zaltrap ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The zaltrap market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Indication: Metastatic Colorectal Cancer (mCRC); Metastatic Breast Cancer2) By Formulation: Injection (100 mg/4 mL, 200 mg/8 mL)
3) By Distribution Channel: Hospitals; Oncology Clinics; Pharmacies
4) By End-User: Adult Patients; Geriatric Patients
Key Companies Profiled: Sanofi S.A.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Sanofi S.A.
